Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT02703571
• Recruitment Status: Terminated
• First Posted: March 9, 2016
• Last Update Posted: December 21, 2020
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.

Condition or disease	Intervention/treatment	Phase
Solid Tumors for Phase Ib; Pancreatic Cancer for Phase II; Colorectal Cancer for Phase II	Drug: ribociclib; Drug: Trametinib	Phase 1

Detailed Description:

Upon careful review of all available efficacy and safety data from the study phase Ib part, Novartis decided to not start the study phase II part.

This decision was in no means triggered by an unfavorable safety profile of the combination. The observed safety profile of the combination represents contributions of the individual safety profile of trametinib and ribociclib.

No new safety signals were observed.

The study was closed early in line with protocol Section 4.4.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 95 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: single group for phase 1b parallel group for phase 2
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
• Actual Study Start Date: June 29, 2016
• Actual Primary Completion Date: September 24, 2019
• Actual Study Completion Date: September 24, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Advanced or metastatic solid tumors; Patients in the Phase I portion of the study who have advanced or metastatic solid tumors	Drug: ribociclib; Combination treatment with LEE and TMT; Other Name: LEE011; Drug: Trametinib; Combination treatment with LEE and TMT; Other Name: TMT212

Outcome Measures

Primary Outcome Measures :

1. Incidence of dose limiting toxicities (DLTs) [ Time Frame: 21-day cycle one of treatment ]

   Phase Ib part:

   The primary variable is the incidence of DLTs during the first 21 days of therapy. Estimation of the MTD of the combination treatment will be based upon the estimation of the probability of DLT during the first 21 days of therapy for patients in the DDS.

2. Objective Response Rate (ORR) [ Time Frame: Until progression of disease up to 1 year ]

   Phase II part:

   The primary variable used to evaluate the efficacy of the ribociclib and trametinib combination is the ORR, defined as the proportion of patients with a best overall confirmed CR or PR, as assessed per RECIST 1.1 by investigator assessment.

Secondary Outcome Measures :

1. Duration of response (DOR) [ Time Frame: Until progression of disease up to 1 year ]

   Phase II part:

   Among patients with a confirmed response (PR or CR) per RECIST 1.1, DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause. The distribution function of DOR will be estimated using the Kaplan-Meier method. The median DOR along with 95% CI will be presented by treatment arm.

2. Time to response [ Time Frame: Until progression of disease up to 1 year ]

   Phase II part:

   Time to overall response of CR or PR (TTR) is defined as the time from start of study drug to first documented response (CR or PR, which must be confirmed subsequently) for patients with a confirmed CR or PR. TTR will be summarized by treatment arm, using descriptive statistics.

3. Disease control rate [ Time Frame: Until progression of disease up to 1 year ]

   Phase II part:

   Disease control rate (DCR) is defined as the proportion of patients with best overall response of CR, PR, or SD per RECIST 1.1. DCR will be estimated and the binomial exact 95% CI will be provided by arm.

4. Progression disease rate [ Time Frame: Until progression of disease up to 1 year ]

   Phase Ib part:

   Progression disease rate defined as the proportion of patients with a progression disease as assessed per RECIST 1.1 by investigator assessment.

5. Progression free survival [ Time Frame: Until progression of disease up to 1 year ]

   Phase Ib and phase II parts:

   Progression-free survival (PFS) is defined as the time from the date of the first dose of study drug to the date of first documented disease progression per RECIST 1.1 or death due to any cause.

6. overall survival [ Time Frame: Until death up to 1 year ]

   Phase Ib and phase II parts:

   Overall survival (OS) is defined as the time from the date of first dose of study drug to the date of death due to any cause.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria (All):

• Written informed consent must
• Patient has histologically and/or cytologically confirmed malignancies:

Phase I:

• Patients with advanced or metastatic solid tumors who have failed at least one prior line of systemic antineoplastic therapy in the advanced setting without a standard of care treatment option available;

Phase II:

• Advanced or metastatic pancreatic adenocarcinoma who have failed at least one prior systemic antineoplastic therapies in the advanced setting
• Advanced or metastatic KRAS-mutant CRC who have failed at least two prior systemic antineoplastic therapies in the advanced setting without a standard of care treatment option available. Testing for KRAS mutation in patients with CRC using locally approved diagnostic kit will be used for eligibility.
• Phase II only: patient must have measurable disease
• Patient has an ECOG performance status 0 or 1.
• Patient has adequate bone marrow and organ function
• Patient must have specified laboratory values within normal limits or corrected to within normal limits with supplements before the first dose of study medication on Cycle 1 Day 1:
• Standard 12-lead ECG values defined

Exclusion Criteria:

Phase II only:

• Patient has received prior treatment with a MEK inhibitor or a CDK4/6 inhibitor.

Phase I and Phase II:

• Patient with a known hypersensitivity to the study drugs or any of the excipients of ribociclib or trametinib.
• Patient is concurrently using other anti-cancer therapy.
• Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to Cycle 1 Day 1
• Patient has received local therapy to liver ≤ 3 months of C1D1
• History of liver disease as follow:
• Cirrhosis
• Autoimmune hepatitis
• Active viral hepatitis
• Portal hypertension
• Drug induced liver steatosis
• Prior systemic anti-cancer treatment within 28 days prior to Cycle 1 Day 1
• Prior therapy with anthracyclines at cumulative doses of 450 mg/ m2 or more for doxorubicin or 900 mg/m2 or more for epirubicin.
• Patient is currently receiving warfarin or other coumadin derived anti-coagulant
• Patient has a history of deep venin thrombosis or pulmonary embolism within 6 months of screening.
• Patient has a concurrent malignancy or malignancy within 3 years prior to Cycle 1 Day 1, with the exception of adequately treated basal or squamous cell carcinoma or curatively resected cervical cancer.
• Patients with central nervous system (CNS) involvement
• Patient has impairment of GI function or GI disease that may significantly alter the absorption of the study drugs
• History of interstitial lung disease or pneumonitis.
• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
• Patient is currently receiving any strong inducers or inhibitors of CYP3A4/5 and/or Substances that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 and cannot be discontinued 7 days prior to Cycle 1 Day 1:
• Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment.
• History of retinal vein occlusion (RVO)

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Locations

United States, Arkansas

Highlands Oncology Group

Fayetteville, Arkansas, United States, 72703

United States, California

City of Hope National Medical Center

Duarte, California, United States, 91010

United States, Connecticut

Yale University School of Medicine

New Haven, Connecticut, United States, 06520

United States, Florida

University of Miami Sylvester Comp Cancer Ctr

Miami, Florida, United States, 33136

United States, Massachusetts

Dana Farber Cancer Center

Boston, Massachusetts, United States, 02215

United States, Texas

UT MD Anderson Cancer Center

Houston, Texas, United States, 77030

Australia, Victoria

Novartis Investigative Site

Melbourne, Victoria, Australia, 3000

Belgium

Novartis Investigative Site

Leuven, Belgium, 3000

Canada, Alberta

Novartis Investigative Site

Edmonton, Alberta, Canada, T6G 1Z2

Canada, British Columbia

Novartis Investigative Site

Vancouver, British Columbia, Canada, V5Z 4E6

Germany

Novartis Investigative Site

Koeln, Germany, 50937

Novartis Investigative Site

Ulm, Germany, 89081

Netherlands

Novartis Investigative Site

Amsterdam, Netherlands, 1066 CX

Novartis Investigative Site

Utrecht, Netherlands, 3584 CX

Spain

Novartis Investigative Site

Barcelona, Catalunya, Spain, 08035

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

More Information

Additional Information:

Results for CTMT212X2106 from the Novartis Clinical Trials Website 

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT02703571
• Other Study ID Numbers: CTMT212X2106; 2015-005019-34 ( EudraCT Number )
• First Posted: March 9, 2016
• Last Update Posted: December 21, 2020
• Last Verified: September 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Trametinib; Ribociclib; LEE011; TMT212; advanced solid tumors; pancreatic cancer; KRAS-mutant colorectal cancer; colorectal cancer; advanced pancreatic cancer; metastatic pancreatic cancer

Additional relevant MeSH terms:

Colorectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases; Trametinib; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action